Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

NCT ID: NCT05607095 Phase: PHASE1 Sponsor: Memorial Sloan Kettering Cancer Center Status: Recruiting

SUMMARY

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

KEY ELIGIBILITY CRITERIA

- * Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma.
- o Patients will be eligible regardless of the number of prior systemic therapies received.
- * Cohort 2: Must have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) that is refractory to at least 1 prior line of systemic therapy
- * Unresectable disease will be defined by an expert sarcoma surgical oncologist as either (a) low likelihood of obtaining an R0 resection or (b) unacceptable morbidity from a surgical procedure
- * Prior systemic therapy in the neoadjuvant or adjuvant setting will count has prior systemic therapy
- * Patients who refuse standard of care chemotherapy will be eligible
- * Cohort 3: Must have a confirmed diagnosis of unresectable or metastatic angiosarcoma that is refractory to at least 1 prior line of systemic therapy
- * Unresectable disease will be defined by an expert sarcoma surgical oncologist as either (a) low likelihood of obtaining an R0 resection or (b) unacceptable morbidity from a surgical procedure
- * Prior systemic therapy in the neoadjuvant or adjuvant setting will count has prior systemic therapy
- * Patients who refuse standard of care chemotherapy will be eligible

ENROLLMENT CONTACT

Lauren Banks, MD, PhD
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Phone: 646-888-6784

Total sites: 2 | 2 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05607095) and public sources. Generated by FindMyCure.ai.